Cell No. : Cell Name
RCB2823 : N0005(>500)
update : 2024/11/11
|
| Comment | Human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. RCB2822, RCB2823, RCB2824 were derived from the same patient. |
| Comment from the depositor | |
| Terms and conditions | |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
Approval Form(C-0006.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
SUGIMOTO, Masanobu
|
| Originator |
SUGIMOTO, Masanobu
|
| Year of deposit |
2008
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
99 years
|
| Tissue |
blood
|
| Classification |
transformed
|
|
Lifespan |
infinite
|
| Morphology |
lymphocyte-like
|
| Contact inhibition |
No
|
| Tumorigenesis |
Yes
|
| Cellosaurus(Expasy) |
CVCL_A6RY
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
Suspension cells
|
Suspension cells
|
| Culture method |
|
浮遊細胞の培養に関する一般的な注意(Japanese)
|
| Culture medium |
RPMI1640 + FBS (10%) , pH 6.0
|
RPMI1640 + 10% FBS
|
| Antibiotics |
Penicillin, Streptomycin
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 6 split
|
| SC frequency |
Subculture : 2 times/week
|
Subculture : 2 times/week
|
| Temperature |
37
℃
|
37
℃
|
| CO2 concentration |
7.5
%
|
7.5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Animal PCR |
|
OK
|
| Virus (HIV) |
|
(-)
|
| Virus (HTLV-1) |
|
(-)
|
| STR(human) |
|
OK
|
| Reference information |
Reference |
13
|
| User's Publication |
0
|
| Reference |
|
874
Futami K, Ishikawa Y, Goto M, Furuichi Y, Sugimoto M.
Role of Werner syndrome gene product helicase in carcinogenesis and in resistance to genotoxins by cancer cells
Cancer Sci
2008
99(5):843-8
PubMed ID: 18312465
DOI: 10.1111/j.1349-7006.2008.00778.x
|
|
875
Sawada K, Noda K, Nakajima H, Shimbara N, Furuichi Y, Sugimoto M.
Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines
Biol Pharm Bull
2005
28(7):1202-7
PubMed ID: 15997098
DOI: 10.1248/bpb.28.1202
|
|
7401
Sugimoto M, Tahara H, Okubo M, Kobayashi T, Goto M, Ide T, Furuichi Y.
WRN gene and other genetic factors affecting immortalization of human B-lymphoblastoid cell lines transformed by Epstein-Barr virus.
Cancer Genet Cytogenet
2004
152(2):95-100
PubMed ID: 15262425
DOI: 10.1016/j.cancergencyto.2003.11.005
|
|
7405
Sugimoto M, Tahara H, Ide T, Furuichi Y.
Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus.
Cancer Res
2004
64(10):3361-4
PubMed ID: 15150084
DOI: 10.1158/0008-5472.CAN-04-0079
|
|
7351
Takahashi T, Kawabe T, Okazaki Y, Itoh C, Noda K, Tajima M, Satoh M, Goto M, Mitsui Y, Tahara H, Ide T, Furuichi Y, Sugimoto M.
In vitro establishment of tumorigenic human B-lymphoblastoid cell lines transformed by Epstein-Barr virus.
DNA Cell Biol
2003
22(11):727-35
PubMed ID: 14659045
DOI: 10.1089/104454903770946700
|
|
877
Toda T, Sugimoto M.
Proteome analysis of Epstein-Barr virus-transformed B-lymphoblasts and the proteome database
J Chromatogr B Analyt Technol Biomed Life Sci
2003
787(1):197-206
PubMed ID: 12659741
DOI: 10.1016/s1570-0232(02)00495-6
|
|
7317
Okubo M, Tsurukubo Y, Higaki T, Kawabe T, Goto M, Murase T, Ide T, Furuichi Y, Sugimoto M.
Clonal chromosomal aberrations accompanied by strong telomerase activity in immortalization of human B-lymphoblastoid cell lines transformed by Epstein-Barr virus.
Cancer Genet Cytogenet
2001
129(1):30-4
PubMed ID: 11520562
DOI: 10.1016/s0165-4608(01)00420-4
|
|
223
Immunological diagnosis of Werner syndrome by down-regulated and truncated gene products
Immunological diagnosis of Werner syndrome by down-regulated and truncated gene products
Hum Genet
1999
105(4):301-7
PubMed ID: 10543396
DOI: 10.1007/s004399900151
|
|
7407
Sugimoto M, Furuichi Y, Ide T, Goto M.
Incorrect us of "immortalization" for B-lymphoblastoid cell lines transformed by Epstein-Barr virus.
J Virol
1999
73(11):9690-1
PubMed ID: 10577062
DOI: 10.1128/JVI.73.11.9690-9691.1999
|
|
222
Okada M, Goto M, Furuichi Y, Sugimoto M.
Differential effects of cytotoxic drugs on mortal and immortalized B-lymphoblastoid cell lines from normal and Werner's syndrome patients
Biol Pharm Bull
1998
21(3):235-9
PubMed ID: 9556152
DOI: 10.1248/bpb.21.235
|
|
221
Kataoka H, Tahara H, Watanabe T, Sugawara M, Ide T, Goto M, Furuichi Y, Sugimoto M.
Immortalization of immunologically committed Epstein-Barr virus-transformed human B-lymphoblastoid cell lines accompanied by a strong telomerase activity
Differentiation
1997
62(4):203-11
PubMed ID: 9503605
DOI: 10.1046/j.1432-0436.1998.6240203.x
|
|
7082
Tahara H, Tokutake Y, Maeda S, Kataoka H, Watanabe T, Satoh M, Matsumoto T, Sugawara M, Ide T, Goto M, Furuichi Y, Sugimoto M.
Abnormal telomere dynamics of B-lymphoblastoid cell strains from Werner's syndrome patients transformed by Epstein-Barr virus.
Oncogene
1997
15(16):1911-20
PubMed ID: 9365237
DOI: 10.1038/sj.onc.1201377
|
|
7412
Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S.
Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes.
J Virol
1994
68(5):3410-4
PubMed ID: 8151802
DOI: 10.1128/JVI.68.5.3410-3414.1994
|
Back
Top
CELL BANK Website